Last reviewed · How we verify
Liquid formulation of HRV vaccine
Liquid formulation of HRV vaccine is a vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Prevention of human rhinovirus infection.
This vaccine stimulates the immune system to recognize and respond to human rhinovirus (HRV) antigens, providing protection against HRV infection.
This vaccine stimulates the immune system to recognize and respond to human rhinovirus (HRV) antigens, providing protection against HRV infection. Used for Prevention of human rhinovirus infection.
At a glance
| Generic name | Liquid formulation of HRV vaccine |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The liquid formulation contains HRV antigens or immunogenic components that trigger both humoral and cellular immune responses. By priming the adaptive immune system against HRV epitopes, the vaccine aims to prevent or reduce the severity of rhinovirus infections, which are among the most common causes of upper respiratory tract infections and can exacerbate asthma and other respiratory conditions.
Approved indications
- Prevention of human rhinovirus infection
Common side effects
- Injection site reactions (pain, erythema, swelling)
- Fever
- Myalgia
- Fatigue
Key clinical trials
- A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Human Rotavirus (HRV) Porcine Circovirus (PCV)-Free Vaccine in Healthy Chinese Infants (PHASE3)
- Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks (PHASE3)
- Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks (PHASE3)
- This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine (PHASE3)
- Immunogenicity, Reactogenicity and Safety Study of Two Different Formulations of GSK Biologicals' Human Rotavirus Vaccine, Rotarix, in Healthy Infants (PHASE3)
- Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks (PHASE3)
- Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix (Human Rotavirus Vaccine) in Infants
- Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine, in Healthy Chinese Infants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Liquid formulation of HRV vaccine CI brief — competitive landscape report
- Liquid formulation of HRV vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Liquid formulation of HRV vaccine
What is Liquid formulation of HRV vaccine?
How does Liquid formulation of HRV vaccine work?
What is Liquid formulation of HRV vaccine used for?
Who makes Liquid formulation of HRV vaccine?
What drug class is Liquid formulation of HRV vaccine in?
What development phase is Liquid formulation of HRV vaccine in?
What are the side effects of Liquid formulation of HRV vaccine?
Related
- Drug class: All vaccine drugs
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of human rhinovirus infection